Related Experiment Video

Updated: Mar 24, 2026

Assessment of Cardiac Function and Energetics in Isolated Mouse Hearts Using 31P NMR Spectroscopy
11:38

Assessment of Cardiac Function and Energetics in Isolated Mouse Hearts Using 31P NMR Spectroscopy

Published on: August 31, 2010

26.8K

Targeting Myocardial Energetics in Nonobstructive Hypertrophic Cardiomyopathy (nHCM): The Role of Ninerafaxstat

Mohammad Hazique1, Arihant Surana2, Birgurman Singh3

  • 1Department of Medicine, Vassar Brother Medical Center / Nuvance Health, Poughkeepsie, NY, USA (hazique405@gmail.com).

Journal of Cardiovascular Pharmacology
|March 17, 2026
PubMed

Insights

Ninerafaxstat, a novel cardiac metabolic modulator, shows promise for treating non-obstructive hypertrophic cardiomyopathy (nHCM) by improving cardiac energy efficiency. This targeted therapy offers a new metabolic approach for nHCM, potentially complementing existing treatments.

Area of Science:

  • Cardiology
  • Metabolic Medicine
  • Pharmacology

Background:

  • Non-obstructive hypertrophic cardiomyopathy (nHCM) presents significant therapeutic challenges due to complex pathophysiology.
  • Current treatments like beta-blockers and calcium channel blockers provide limited relief and do not address metabolic deficits.
  • There is a need for therapies that target the underlying metabolic dysfunction in nHCM.

Purpose of the Study:

  • To review emerging targeted therapies for nHCM, with a focus on ninerafaxstat.
  • To evaluate ninerafaxstat's mechanism of action as a cardiac metabolic modulator.
  • To assess the clinical trial data for ninerafaxstat and compare its potential with other novel agents.

Main Methods:

  • Review of clinical trial data, including the Phase 2 IMPROVE-HCM trial.
  • Analysis of ninerafaxstat's mechanism: inhibition of 3-ketoacyl-CoA thiolase (3-KAT) to shift substrate utilization from fatty acids to glucose.
  • Comparison with other emerging therapies like myosin inhibitors (aficamten, mavacamten) and gene therapies.

Main Results:

  • The IMPROVE-HCM trial showed ninerafaxstat improved ventilatory efficiency (VE/VCO2 slope) and reduced left atrial remodeling in severe nHCM subgroups.
  • Ninerafaxstat demonstrated a favorable safety profile and enhanced quality of life.
  • Unlike myosin inhibitors, ninerafaxstat directly addresses metabolic dysfunction and energy deficits in the heart.

Conclusions:

  • Ninerafaxstat represents a paradigm shift in nHCM treatment, offering a metabolic foundation for precision medicine.
  • It has the potential to synergize with sarcomere-targeted therapies for dual-pathway efficacy.
  • Further Phase 3 trials are needed to confirm long-term benefits on functional capacity, metabolic markers, and survival.

Keywords:
Cardiac energeticsHypertrophic cardiomyopathyMetabolic modulationNinerafaxstat

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.8K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
661
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
615
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
740
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
769
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
783
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.9K